Strain-Specific Immunity Discovered for Lyme Disease
|
By LabMedica International staff writers Posted on 17 Apr 2014 |

Image: Scanning electron micrograph of the spirochete Borrelia burgdorferi, long, slender bacteria that typically take on a coiled shape. Infection with this bacterium causes Lyme disease (Photo courtesy of Tina Carvalho).
Many patients treated for early Lyme disease incur another infection in subsequent years, suggesting that previous exposure to Borrelia burgdorferi may not elicit a protective immune response.
At least 16 different strains of the Lyme disease bacterium have been shown to infect humans in the United States of America, so being bitten by a tick carrying a different strain of the disease is entirely possible.
Scientists at the University of Pennsylvania (Philadelphia, PA, USA) and their collaborators analyzed the occurrence of identical strains of B. burgdorferi in a cohort of 17 patients with multiple episodes of culture-confirmed erythema migrans. They used both multinomial probability analyses and a stochastic simulation model to evaluate whether only one or fewer of 17 patients could have identical strains of B. burgdorferi in recurrent infections due to chance alone. All analyses estimated the probability of recovering a particular strain of B. burgdorferi from a patient due to chance alone, based on empirical patient data.
The model allowed the researchers to vary assumptions such as the presence or absence of type-specific immunity, the duration of immunity, and the length of time a patient was accessible to having been bitten by a tick, or in other words, the time from the first visit to the clinic to the last visit, or from the first visit to the completion of the study.
The results of all of the simulations indicated that strain-specific immunity would need to last a minimum of four years in order to result in the suite of infections that the 17 patients acquired. When the model parameters were used with actual data from 200 patients who had been infected at least once with a known strain of B. burgdorferi, the simulation indicated that immunity lasts in the range of six to nine years. The only patient infected by the same strain twice actually had Lyme disease four times in six years, contracting K strain twice, five years apart, with an infection by a different strain in between.
The authors concluded that it is highly unlikely that only one of 17 patients would have been infected with an identical strain of B. burgdorferi in a recurrent episode of Lyme disease in the absence of strain-specific immunity. Furthermore, the duration of strain-specific immunity needed to be at least four years to explain the data actually observed. The presence and long duration of strain-specific immunity that the models suggest imply that humans, once infected, are highly unlikely to acquire a subsequent infection caused by the same strain of B. burgdorferi.
The fact that the strain-specific immunity is lasting has implications for vaccine design. Dustin Brisson, PhD, an assistant professor and senior author of the study, said, “If you could make a vaccine that covers several of these strains, you could substantially reduce the probability of infection in vaccinated people. The vaccine could last several years, perhaps requiring a booster once every several years.” The study was published in the April 2014 issue of the journal Infection and Immunity.
Related Links:
University of Pennsylvania
At least 16 different strains of the Lyme disease bacterium have been shown to infect humans in the United States of America, so being bitten by a tick carrying a different strain of the disease is entirely possible.
Scientists at the University of Pennsylvania (Philadelphia, PA, USA) and their collaborators analyzed the occurrence of identical strains of B. burgdorferi in a cohort of 17 patients with multiple episodes of culture-confirmed erythema migrans. They used both multinomial probability analyses and a stochastic simulation model to evaluate whether only one or fewer of 17 patients could have identical strains of B. burgdorferi in recurrent infections due to chance alone. All analyses estimated the probability of recovering a particular strain of B. burgdorferi from a patient due to chance alone, based on empirical patient data.
The model allowed the researchers to vary assumptions such as the presence or absence of type-specific immunity, the duration of immunity, and the length of time a patient was accessible to having been bitten by a tick, or in other words, the time from the first visit to the clinic to the last visit, or from the first visit to the completion of the study.
The results of all of the simulations indicated that strain-specific immunity would need to last a minimum of four years in order to result in the suite of infections that the 17 patients acquired. When the model parameters were used with actual data from 200 patients who had been infected at least once with a known strain of B. burgdorferi, the simulation indicated that immunity lasts in the range of six to nine years. The only patient infected by the same strain twice actually had Lyme disease four times in six years, contracting K strain twice, five years apart, with an infection by a different strain in between.
The authors concluded that it is highly unlikely that only one of 17 patients would have been infected with an identical strain of B. burgdorferi in a recurrent episode of Lyme disease in the absence of strain-specific immunity. Furthermore, the duration of strain-specific immunity needed to be at least four years to explain the data actually observed. The presence and long duration of strain-specific immunity that the models suggest imply that humans, once infected, are highly unlikely to acquire a subsequent infection caused by the same strain of B. burgdorferi.
The fact that the strain-specific immunity is lasting has implications for vaccine design. Dustin Brisson, PhD, an assistant professor and senior author of the study, said, “If you could make a vaccine that covers several of these strains, you could substantially reduce the probability of infection in vaccinated people. The vaccine could last several years, perhaps requiring a booster once every several years.” The study was published in the April 2014 issue of the journal Infection and Immunity.
Related Links:
University of Pennsylvania
Latest Immunology News
- New Test Distinguishes Vaccine-Induced False Positives from Active HIV Infection
- Gene Signature Test Predicts Response to Key Breast Cancer Treatment
- Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
- Blood-Based Liquid Biopsy Model Analyzes Immunotherapy Effectiveness
- Signature Genes Predict T-Cell Expansion in Cancer Immunotherapy
- Molecular Microscope Diagnostic System Assesses Lung Transplant Rejection
- Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer
- Luminescent Probe Measures Immune Cell Activity in Real Time
- Blood-Based Immune Cell Signatures Could Guide Treatment Decisions for Critically Ill Patients
- Novel Tool Predicts Most Effective Multiple Sclerosis Medication for Patients
- Companion Diagnostic Test for CRC Patients Identifies Eligible Treatment Population
- Novel Tool Uses Deep Learning for Precision Cancer Therapy
- Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients
- Novel Multiplex Assay Supports Diagnosis of Autoimmune Vasculitis
- Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer
- Simple Genetic Testing Could Predict Treatment Success in Multiple Sclerosis Patients
Channels
Clinical Chemistry
view channel
Chemical Imaging Probe Could Track and Treat Prostate Cancer
Prostate cancer remains a leading cause of illness and death among men, with many patients eventually developing resistance to standard hormone-blocking therapies. These drugs often lose effectiveness... Read more
Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
Creatinine has long been the standard for measuring kidney filtration, while cystatin C — a protein produced by all human cells — has been recommended as a complementary marker because it is influenced... Read moreMolecular Diagnostics
view channel
Simple Urine Test to Revolutionize Bladder Cancer Diagnosis and Treatment
Bladder cancer is one of the most common and deadly urological cancers and is marked by a high rate of recurrence. Diagnosis and follow-up still rely heavily on invasive cystoscopy or urine cytology, which... Read more
Blood Test to Enable Earlier and Simpler Detection of Liver Fibrosis
Persistent liver damage caused by alcohol misuse or viral infections can trigger liver fibrosis, a condition in which healthy tissue is gradually replaced by collagen fibers. Even after successful treatment... Read moreHematology
view channel
Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read moreMicrobiology
view channel
Rapid Diagnostic Test Matches Gold Standard for Sepsis Detection
Sepsis kills 11 million people worldwide every year and generates massive healthcare costs. In the USA and Europe alone, sepsis accounts for USD 100 billion in annual hospitalization expenses.... Read moreRapid POC Tuberculosis Test Provides Results Within 15 Minutes
Tuberculosis remains one of the world’s deadliest infectious diseases, and reducing new cases depends on identifying individuals with latent infection before it progresses. Current diagnostic tools often... Read more
Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples
Bloodstream infections in sepsis progress quickly and demand rapid, precise diagnosis. Current blood-culture methods often take one to five days to identify the pathogen, leaving clinicians to treat blindly... Read morePathology
view channel
Tunable Cell-Sorting Device Holds Potential for Multiple Biomedical Applications
Isolating rare cancer cells from blood is essential for diagnosing metastasis and guiding treatment decisions, but remains technically challenging. Many existing techniques struggle to balance accuracy,... Read moreAI Tool Outperforms Doctors in Spotting Blood Cell Abnormalities
Diagnosing blood disorders depends on recognizing subtle abnormalities in cell size, shape, and structure, yet this process is slow, subjective, and requires years of expert training. Even specialists... Read moreTechnology
view channel
Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Identifying which genetic variants actually cause disease remains one of the biggest challenges in genomic medicine. Each person carries tens of thousands of DNA changes, yet only a few meaningfully alter... Read more
AI Saliva Sensor Enables Early Detection of Head and Neck Cancer
Early detection of head and neck cancer remains difficult because the disease produces few or no symptoms in its earliest stages, and lesions often lie deep within the head or neck, where biopsy or endoscopy... Read moreIndustry
view channel
Abbott Acquires Cancer-Screening Company Exact Sciences
Abbott (Abbott Park, IL, USA) has entered into a definitive agreement to acquire Exact Sciences (Madison, WI, USA), enabling it to enter and lead in fast-growing cancer diagnostics segments.... Read more








